Rapid growth in industrial research and development of antibody drug conjugate (ADC) production has occurred over the last two decades, resulting in more than 10 ADCs that have received market approval by the Food and Drug Administration as monotherapies. During this timeframe, significant efforts aimed at generating “best in class” ADCs have been undertaken including ADC target selection, payload diversity, cleavable linker design, hydrophilic linker design, site-specific conjugation technology, and application of next generation clinical and translational strategies. Furthermore, novel applications such as multi-specific antibody-based bioconjugates, antibody immobilization, antibody sensors, antibody-oligonucleotide conjugates, or antibody-protac conjugates have emerged. In this special issue, we will highlight recent work, selected from across the ADC field, that describes novel and important laboratory and clinical advances.
Dr. Brian A. Mendelsohn
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Correction: Schwach et al. More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Frontiers in Bioscience-Landmark. 2022; 27: 240Jonathan Schwach, Mustafa Abdellatif, Andreas StenglFront. Biosci. (Landmark Ed) 2023, 28(4), 79; https://doi.org/10.31083/j.fbl2708240corr46Downloads215Views
- Antibody-Drug Conjugates Targeting Tumor-Specific Mucin GlycoepitopesJulyanne Brassard, Michael R. Hughes, Calvin D. Roskelley, Kelly M. McNagnyFront. Biosci. (Landmark Ed) 2022, 27(11), 301; https://doi.org/10.31083/j.fbl2711301437Downloads2Citations678Views
- A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab DeruxtecanEvolène Deslignière, Hélène Diemer, Stéphane Erb, Pierre Coliat, ... Sarah CianféraniFront. Biosci. (Landmark Ed) 2022, 27(10), 290; https://doi.org/10.31083/j.fbl2710290541Downloads2Citations1145Views
- More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug ConjugatesJonathan Schwach, Mustafa Abdellatif, Andreas StenglFront. Biosci. (Landmark Ed) 2022, 27(8), 240; https://doi.org/10.31083/j.fbl27082401005Downloads8Citations1052Views
- Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®Takuya Seki, Kei Yamada, Yuri Ooba, Tomohiro Fujii, ... Tatsuya OkuzumiFront. Biosci. (Landmark Ed) 2022, 27(8), 234; https://doi.org/10.31083/j.fbl2708234229Downloads5Citations552Views